Many head and neck cancers are able to escape immune responses in a variety of ways.
Additionally tumors can escape antigen-directed therapies by loss or down-regulation of the associated antigens, as well demonstrated after checkpoint blockade immunotherapy and CAR-T cell therapy though more recent data indicate that this may be prevented by localized bystander killing mediated by fasL/fas.